[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
YL Wu, G Chen, J Feng, XQ Liu, C Wang, S Zhang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small …
C Zhou, YL Wu, G Chen, J Feng… - Annals of oncology …, 2015 - pubmed.ncbi.nlm.nih.gov
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - Annals of Oncology …, 2015 - europepmc.org
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - Annals of …, 2015 - annalsofoncology.org
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
[引用][C] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - cir.nii.ac.jp
Final overall survival results from a randomised, phase III study of erlotinib versus
chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung …
chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung …